Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana

Abstract Introduction The West African HIV/AIDS epidemic, historically driven by HIV-1 CRF02_AG, other recombinant forms and HIV-2, remains less researched for various preventive and therapeutic interventions. We established the WACCBIP long-term HIV Infection Cohort (WHICH Study) to investigate the...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark Appeaning, Edwin Magomere, Alberta Mawulawoe Abotsi, Nana Ama Yeboaa Amoako, Kirk Elorm Kouffie, Becky Ewurama Tetteh, Bridget Nana Darkoa Quist, Christèle Nguepou Tchopba, Gloria Akosua Ansa, Evelyn Yayra Bonney, Peter Kojo Quashie
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Virology Journal
Subjects:
Online Access:https://doi.org/10.1186/s12985-025-02873-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849344840545861632
author Mark Appeaning
Edwin Magomere
Alberta Mawulawoe Abotsi
Nana Ama Yeboaa Amoako
Kirk Elorm Kouffie
Becky Ewurama Tetteh
Bridget Nana Darkoa Quist
Christèle Nguepou Tchopba
Gloria Akosua Ansa
Evelyn Yayra Bonney
Peter Kojo Quashie
author_facet Mark Appeaning
Edwin Magomere
Alberta Mawulawoe Abotsi
Nana Ama Yeboaa Amoako
Kirk Elorm Kouffie
Becky Ewurama Tetteh
Bridget Nana Darkoa Quist
Christèle Nguepou Tchopba
Gloria Akosua Ansa
Evelyn Yayra Bonney
Peter Kojo Quashie
author_sort Mark Appeaning
collection DOAJ
description Abstract Introduction The West African HIV/AIDS epidemic, historically driven by HIV-1 CRF02_AG, other recombinant forms and HIV-2, remains less researched for various preventive and therapeutic interventions. We established the WACCBIP long-term HIV Infection Cohort (WHICH Study) to investigate the dynamics of HIV epidemic in Ghana. This report evaluates viral load dynamics, immune responses, and organ-level metabolic changes following antiretroviral therapy (ART) initiation. Method We collected blood samples, medical, and demographic data from ART-naïve individuals at baseline and six months post-ART, and from ART-experienced individuals at a single time point. Participants, aged 10 years and above, were purposively enrolled from six health facilities. Laboratory analyses included viral load, CD4 and CD8 counts, co-infection screening (hepatitis B/C, syphilis), liver and kidney function tests, haemoglobin estimation, and HIV-1/2 typing. Chi-square and logistic regression analyses were used to assess associations between participant demographics and clinical data with uncontrolled viremia and immune recovery. Results A total of 426 participants were recruited, comprising 159 ART-naïve and 267 ART-experienced individuals, with a mean age of 41.5 years. Median ART duration for ART-experienced was greater than 5 years. Infections included HIV-1 (78.6%), HIV-2 (2.1%), and dual HIV-1&2 (19.2%). Common comorbidities were anaemia (54.9%), hepatitis B (9.5%), and hypertension (8.2%). Most participant (97.9%) were on dolutegravir-anchored regimen. Among ART-naïve individuals, median viral load decreased from log10 5.16 at baseline to log10 4.64 copies/mL after six months (p = 0.0156). Median viral load for the ART-experienced arm was log10 3.23 copies/mL. Median CD4 count increased from 290 cells/mm³ in ART-naïve participants to 504 cells/mm³ at six-months post-ART (p = 0.0003) and 581 cells/mm³ in ART-experienced participants (p < 0.0001). ART-naïve participants were 19 times more likely to have unsuppressed viral loads at baseline compared to ART-experienced participants. ARTnaïve- participants had significantly decreased odds of immune recovery (aOR = 0.35, 95% CI: 0.140–0.85, p = 0.021), as did those with low CD4/CD8 ratio (aOR = 0.06, 95% CI: 0.02–0.20; p < 0.001). Kidney function and haemoglobin levels were significantly improved six-month post-ART among the ART-naïve group. Conclusion This study highlights the significant reduction in viral load and improved immune recovery following ART initiation despite uncontrolled viremia in a subset of participants. This cohort presents an opportunity to study Ghana’s local HIV epidemic, including HIV-1 and HIV-2, and impact of ART on disease progression.
format Article
id doaj-art-1c8f866d21c94b478fbb616d8cdd07bd
institution Kabale University
issn 1743-422X
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series Virology Journal
spelling doaj-art-1c8f866d21c94b478fbb616d8cdd07bd2025-08-20T03:42:34ZengBMCVirology Journal1743-422X2025-07-0122111410.1186/s12985-025-02873-wSlow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in GhanaMark Appeaning0Edwin Magomere1Alberta Mawulawoe Abotsi2Nana Ama Yeboaa Amoako3Kirk Elorm Kouffie4Becky Ewurama Tetteh5Bridget Nana Darkoa Quist6Christèle Nguepou Tchopba7Gloria Akosua Ansa8Evelyn Yayra Bonney9Peter Kojo Quashie10West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaPublic Health Department, University of Ghana Health ServicesNoguchi Memorial Institute for Medical Research, University of GhanaWest African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of GhanaAbstract Introduction The West African HIV/AIDS epidemic, historically driven by HIV-1 CRF02_AG, other recombinant forms and HIV-2, remains less researched for various preventive and therapeutic interventions. We established the WACCBIP long-term HIV Infection Cohort (WHICH Study) to investigate the dynamics of HIV epidemic in Ghana. This report evaluates viral load dynamics, immune responses, and organ-level metabolic changes following antiretroviral therapy (ART) initiation. Method We collected blood samples, medical, and demographic data from ART-naïve individuals at baseline and six months post-ART, and from ART-experienced individuals at a single time point. Participants, aged 10 years and above, were purposively enrolled from six health facilities. Laboratory analyses included viral load, CD4 and CD8 counts, co-infection screening (hepatitis B/C, syphilis), liver and kidney function tests, haemoglobin estimation, and HIV-1/2 typing. Chi-square and logistic regression analyses were used to assess associations between participant demographics and clinical data with uncontrolled viremia and immune recovery. Results A total of 426 participants were recruited, comprising 159 ART-naïve and 267 ART-experienced individuals, with a mean age of 41.5 years. Median ART duration for ART-experienced was greater than 5 years. Infections included HIV-1 (78.6%), HIV-2 (2.1%), and dual HIV-1&2 (19.2%). Common comorbidities were anaemia (54.9%), hepatitis B (9.5%), and hypertension (8.2%). Most participant (97.9%) were on dolutegravir-anchored regimen. Among ART-naïve individuals, median viral load decreased from log10 5.16 at baseline to log10 4.64 copies/mL after six months (p = 0.0156). Median viral load for the ART-experienced arm was log10 3.23 copies/mL. Median CD4 count increased from 290 cells/mm³ in ART-naïve participants to 504 cells/mm³ at six-months post-ART (p = 0.0003) and 581 cells/mm³ in ART-experienced participants (p < 0.0001). ART-naïve participants were 19 times more likely to have unsuppressed viral loads at baseline compared to ART-experienced participants. ARTnaïve- participants had significantly decreased odds of immune recovery (aOR = 0.35, 95% CI: 0.140–0.85, p = 0.021), as did those with low CD4/CD8 ratio (aOR = 0.06, 95% CI: 0.02–0.20; p < 0.001). Kidney function and haemoglobin levels were significantly improved six-month post-ART among the ART-naïve group. Conclusion This study highlights the significant reduction in viral load and improved immune recovery following ART initiation despite uncontrolled viremia in a subset of participants. This cohort presents an opportunity to study Ghana’s local HIV epidemic, including HIV-1 and HIV-2, and impact of ART on disease progression.https://doi.org/10.1186/s12985-025-02873-wWHICH studyHIV cohortHIV cure researchWest AfricaGhanaHIV-1
spellingShingle Mark Appeaning
Edwin Magomere
Alberta Mawulawoe Abotsi
Nana Ama Yeboaa Amoako
Kirk Elorm Kouffie
Becky Ewurama Tetteh
Bridget Nana Darkoa Quist
Christèle Nguepou Tchopba
Gloria Akosua Ansa
Evelyn Yayra Bonney
Peter Kojo Quashie
Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana
Virology Journal
WHICH study
HIV cohort
HIV cure research
West Africa
Ghana
HIV-1
title Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana
title_full Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana
title_fullStr Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana
title_full_unstemmed Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana
title_short Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana
title_sort slow virologic control but strong immune and metabolic recovery with dolutegravir anchored therapy in an hiv cohort in ghana
topic WHICH study
HIV cohort
HIV cure research
West Africa
Ghana
HIV-1
url https://doi.org/10.1186/s12985-025-02873-w
work_keys_str_mv AT markappeaning slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT edwinmagomere slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT albertamawulawoeabotsi slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT nanaamayeboaaamoako slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT kirkelormkouffie slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT beckyewuramatetteh slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT bridgetnanadarkoaquist slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT christelenguepoutchopba slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT gloriaakosuaansa slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT evelynyayrabonney slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana
AT peterkojoquashie slowvirologiccontrolbutstrongimmuneandmetabolicrecoverywithdolutegraviranchoredtherapyinanhivcohortinghana